Information for the public

What has NICE said?

What has NICE said?

Idelalisib (Zydelig), given with a drug called rituximab, is recommended as a possible treatment for adults with:

  • untreated chronic lymphocytic leukaemia, only if they have certain genetic chatacteristics

  • chronic lymphocytic leukaemia, only if it has been treated but has come back within 2¬†years.

What does this mean for me?

If you have chronic lymphocytic leukaemia, and your doctor thinks that idelalisib is the right treatment, you should be able to have the treatment on the NHS.

Idelalisib should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking idelalisib until you and your doctor decide it is the right time to stop.

  • Information Standard